Youtor
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=kE8HDZQ22Mk
Pomalidomide, an investigational third-generation immunomodulatory drug, was more effective when combined with low-dose dexamethasone than high-dose in a clinical trial presented at the annual meeting of the American Society of Hematology. Patrice Wendling interviews Dr. Meletios A. Dimopoulos on why reducing toxicity is important in multiple myeloma regimens. For ongoing coverage of ASH, visit http://www.oncologyreport.com.
#############################
